Inhibitors of serine proteases, particularly HCV NS3-NS4A...

Details Inhibitors of serine proteases, particularly HCV NS3-NS4A... Inhibitors of serine proteases, particularly HCV NS3-NS4A...

2008-04-10

2010-06-29

Anderson, Rebecca L (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S255060, C544S406000

Reexamination Certificate

active

07745444

ABSTRACT:
The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.

REFERENCES:
patent: 4499082 (1985-02-01), Shenvi
patent: 5384410 (1995-01-01), Kettner
patent: 5484801 (1996-01-01), Al-Razzak et al.
patent: 5502061 (1996-03-01), Hui
patent: 5807876 (1998-09-01), Armistead et al.
patent: 5866684 (1999-02-01), Attwood
patent: 5948436 (1999-09-01), Al-Razzak et al.
patent: 5990276 (1999-11-01), Zhang et al.
patent: 6018020 (2000-01-01), Attwood
patent: 6037157 (2000-03-01), Norbeck et al.
patent: 6054472 (2000-04-01), Armistead et al.
patent: 6211338 (2001-04-01), Macolm
patent: 6265380 (2001-07-01), Tung
patent: 6344465 (2002-02-01), Armistead et al.
patent: 6420380 (2002-07-01), Llinas-Brunet
patent: 6498178 (2002-12-01), Stamos et al.
patent: 6541496 (2003-04-01), Armistead et al.
patent: 6608067 (2003-08-01), Tung
patent: 6617309 (2003-09-01), Tung
patent: 6800434 (2004-10-01), Saksena
patent: 6900434 (2005-05-01), Kuwabara
patent: 6909000 (2005-06-01), Farmer
patent: 6914122 (2005-07-01), Venkatraman
patent: 7109172 (2006-09-01), Britt
patent: 7122627 (2006-10-01), Priestley
patent: 7208600 (2007-04-01), Cottrell
patent: 7241796 (2007-07-01), Farmer
patent: 7273885 (2007-09-01), Pitlik
patent: 7365092 (2008-04-01), Cottrell
patent: 7388017 (2008-06-01), Tung
patent: 7494988 (2009-02-01), Perni
patent: 2002/0123468 (2002-09-01), Han
patent: 2003/0236242 (2003-12-01), Perni et al.
patent: 2004/0018986 (2004-01-01), Pitlik et al.
patent: 2004/0077600 (2004-04-01), Tung
patent: 2005/0080017 (2005-04-01), Cottrell et al.
patent: 2005/0090450 (2005-04-01), Farmer et al.
patent: 2005/0119189 (2005-06-01), Cottrell
patent: 2005/0197299 (2005-09-01), Babine
patent: 2005/0215486 (2005-09-01), Cottrell
patent: 2006/0089385 (2006-04-01), Cui
patent: 2006/0105978 (2006-05-01), Chu
patent: 2006/0211629 (2006-09-01), Britt
patent: 2007/0087973 (2007-04-01), Tanoury
patent: 2007/0105781 (2007-05-01), Lyons
patent: 2007/0161789 (2007-07-01), Cottrell
patent: 2007/0179167 (2007-08-01), Cottrell
patent: 2007/0231262 (2007-10-01), Lin
patent: 2007/0292933 (2007-12-01), Pitlik
patent: 2008/0045480 (2008-02-01), Farmer
patent: 2008/0082155 (2008-04-01), Fischell
patent: 2008/0125376 (2008-05-01), Cottrell
patent: 2008/0267915 (2008-10-01), Lin
patent: 2009/0022688 (2009-01-01), Farmer
patent: 2009/0098802 (2009-04-01), Talamo
patent: 2009/0143312 (2009-06-01), Tung
patent: 0 195 212 (1986-09-01), None
patent: 0 363 284 (1990-04-01), None
patent: 0 417 721 (1990-09-01), None
patent: 0 675 112 (1995-03-01), None
patent: WO 92/12140 (1992-07-01), None
patent: WO 93/25574 (1993-12-01), None
patent: WO 94/14436 (1994-07-01), None
patent: WO 95/07696 (1995-03-01), None
patent: WO 95/09614 (1995-04-01), None
patent: WO 95/35308 (1995-12-01), None
patent: WO 97/40028 (1997-10-01), None
patent: WO 97/43310 (1997-11-01), None
patent: WO 98/17679 (1998-04-01), None
patent: WO 98/22496 (1998-05-01), None
patent: WO 98/40381 (1998-09-01), None
patent: WO 98/46630 (1998-10-01), None
patent: WO 99/07733 (1999-02-01), None
patent: WO 99/07734 (1999-02-01), None
patent: WO 99/37666 (1999-07-01), None
patent: WO 99/38888 (1999-08-01), None
patent: WO 99/50230 (1999-10-01), None
patent: WO 99/64442 (1999-12-01), None
patent: WO 00/09543 (2000-02-01), None
patent: WO 00/09558 (2000-02-01), None
patent: WO 00/16767 (2000-03-01), None
patent: WO 00/31129 (2000-06-01), None
patent: WO 00/56331 (2000-09-01), None
patent: WO 00/59929 (2000-10-01), None
patent: WO 01/02424 (2001-01-01), None
patent: WO 01/07407 (2001-02-01), None
patent: WO 01/16300 (2001-03-01), None
patent: WO 01/32691 (2001-05-01), None
patent: WO 01/40262 (2001-06-01), None
patent: WO 01/58929 (2001-08-01), None
patent: WO 01/64678 (2001-09-01), None
patent: WO 01/74768 (2001-10-01), None
patent: WO 01/77113 (2001-10-01), None
patent: WO 01/81325 (2001-11-01), None
patent: WO 02/07761 (2002-01-01), None
patent: WO 02/08187 (2002-01-01), None
patent: WO 02/08198 (2002-01-01), None
patent: WO 02/08244 (2002-01-01), None
patent: WO 02/08251 (2002-01-01), None
patent: WO 02/08256 (2002-01-01), None
patent: WO 02/18369 (2002-03-01), None
patent: WO 02/22828 (2002-03-01), None
patent: WO 02/48116 (2002-06-01), None
patent: WO 02/48157 (2002-06-01), None
patent: WO 02/48172 (2002-06-01), None
patent: WO 02/060926 (2002-08-01), None
patent: WO 02/079234 (2002-10-01), None
patent: WO 03/006490 (2003-01-01), None
patent: WO 03/035060 (2003-05-01), None
patent: WO 03/053349 (2003-07-01), None
patent: WO 03/064416 (2003-08-01), None
patent: WO 03/087092 (2003-10-01), None
patent: WO 03/099274 (2003-12-01), None
patent: WO 03/099316 (2003-12-01), None
patent: WO 2004/037855 (2004-05-01), None
patent: WO 2004/092161 (2004-10-01), None
patent: WO 2004/092162 (2004-10-01), None
patent: WO 2004/103996 (2004-12-01), None
patent: WO 2006/002539 (2006-01-01), None
patent: WO 2008/106058 (2008-09-01), None
Alberti et al., “Natural History of Hepatitis C”,J. Hepatology, 31: 17-24 (1999).
Alter et al., “The Epidemiology of Viral Hepatitis in the United States”,Gastroenterol. Clin. North Am., 23:437-455 (1994).
Alter, “Hepatitis C Virus Infection in the United States”,J. Hepatology, 31: 88-91 (1999).
Bartenschlager et al., “Nonstructural Protein 3 of the Hepatitis C Virus Encodes a Serine-Type Proteinase Required for Cleavage at the NS3/4 and NS4/5 Junctions”,J. Virol., 67: 3835-3844 (1993).
Beaulieu and Llinàs-Brunet, “Therapies for Hepatitis C Infection: Targeting the Non-Structural Proteins”,Current Medicinal Chemistry-Anti-Infective Agents, 1: 163-176 (2002).
Di Bisceglie and Hoofnagle, “Optimal Therapy of Hepatitis C”,Hepatology, 36: S121-S127 (2002).
Chambers et al., “Evidence that the N-terminal Domain of Nonstructural Protein NS3 From Yellow Fever Virus Is a Serine Protease Responsible for Site-Specific Cleavages in the Viral Polyprotein”,Proc. Natl. Acad. Sci. USA, 87: 8898-8902 (1990).
Choo et al., “Genetic Organization and Diversity of the Hepatitis C Virus”,Proc. Natl. Acad. Sci. USA, 88: 2451-2455 (1991).
Clayette et al., “IFN-τ, A New Type I IFN with Antiretroviral Activity”,Pathol. Biol. (Paris), 47: 553-559 (1999).
Davis et al., “Future Options for the Management of Hepatitis C.”,Seminars in Liver Disease, 19: 103-112 (1999).
Dunsdon et al., “Solid Phase Synthesis of Aminoboronic Acids: Potent Inhibitors of the Hepatitis C Virus NS3 Proteinase”,Bioorg. Med. Chem. Lett., 10: 1577-1579 (2000).
Dymock, “Emerging Therapies for Hepatitis C Virus Infections”,Emerging Drugs, 6: 13-42 (2001).
Gettins, et al., “Serpin Structure, Mechanism, and Function,”Chem. Rev., 102:4751-4803 (2002).
Grakoui et al., “Expression and Identification of Hepatitis C Virus Polyprotein Cleavage Products”,J. Virol., 67: 1385-1395 (1993).
Grakoui et al., “Characterization of the Hepatitis C Virus-Encoded Serine Proteinase: Determination of Proteinase-Dependent Polyprotein Cleavage Sites”,J. Virol., 67: 2832-2843 (1993).
Han et al., “α-Ketoamides, α-Ketoesters and α-Diketones as HCV NS3 Protease Inhibitors”,Bioorg. Med. Chem. Lett., 10: 711-713 (2000).
Heathcote et al. “Peginterferon Alpha-2a in Patients with Chronic Hepatitis C and Cirrhosis”,New England Journal of Medicine, 343: 1673-1680 (2000).
Iwarson, “The Natural Course of Chronic Hepati

Affiliated with

Also associated with

Rating

Inhibitors of serine proteases, particularly HCV NS3-NS4A... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Inhibitors of serine proteases, particularly HCV NS3-NS4A..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of serine proteases, particularly HCV NS3-NS4A... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4166600